newsfilter
← Latest News
GlobeNewswire·

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,